Epidermal growth factor receptor and human epidermal growth factor receptor 2 gene polymorphisms in endometrial cancer in a Japanese population

Reproductive Sciences

Volumn 14, Issue 4, 2007, Pages 349-357

  Kitao, Keisuke ^a   Yoshida, Shigeki ^a   Kennedy, Stephen ^b   Takemura, Naoya ^a   Sugimoto, Makoto ^a   Deguchi, Masashi ^a   Ohara, Noriyuki ^a   Maruo, Takeshi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Endometrial cancer; Epidermal growth factor receptor; Gene polymorphism; Human epidermal growth factor receptor 2; Polymerase chain reaction restriction fragment length polymorphism

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ADENINE; ERBB2 PROTEIN, HUMAN; GUANINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; ENDOMETRIUM CANCER; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ASIAN; ENDOMETRIUM TUMOR; GENETIC POLYMORPHISM; GENETICS; JAPAN; MIDDLE AGED; PATHOLOGY; PROTO ONCOGENE; REFERENCE VALUE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENINE; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, ERBB-2; GUANINE; HUMANS; JAPAN; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REFERENCE VALUES;

EID: 34648813962     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719107303383     Document Type: Article

References (43)

1. Persson I., Adami HO, Bergkvist L., et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ. 1989 ; 298: 147-151.
2. Sherman ME T heories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000 ; 13: 295-308.
3. Emons G., Fleckenstein G., Hinney B., Huschmand A., Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer. 2000 ; 7: 227-242.
4. Olayioye MA, Neve RM, Lane HA, Hynes NE The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000 ; 19: 3159-3167.
5. Laskin JJ, Sandler AB Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev. 2004 ; 30: 1-17.
6. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001 ; 92: 1331-1346.
7. Uegaki K., Nio Y., Inoue Y., et al. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res. 1997 ; 17: 3841-3847.
8. Rusch V., Klimstra D., Venkatraman E., Pisters PW, Langenfeld J., Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res. 1997 ; 3: 515-522.
9. Bartlett JM, Langdon SP, Simpson BJ, et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer. 1996 ; 73: 301-306.
10. Walker RA, Dearing SJ Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat. 1999 ; 53: 167-176.
11. Rubin Grandis J., Melhem MF, Gooding WE, et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998 ; 90: 824-832.
12. Volm M., Rittgen W., Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer. 1998 ; 77: 663-669.
13. Plowman GD, Whitney GS, Neubauer MG, et al. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc Natl Acad Sci U S A. 1990 ; 87: 4905-4909.
14. Plowman GD, Culouscou JM, Whitney GS, et al. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A. 1993 ; 90: 1746-1750.
15. Kuan CT, Wikstrand CJ, Bigner DD EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer. 2001 ; 8: 83-96.
16. Khalifa MA, Abdoh AA, Mannel RS, Haraway SD, Walker JL, Min KW Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer. 1994 ; 73: 370-376.
17. Wang D., Konishi I., Koshiyama M., et al. Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas: correlation with clinicopathologic and sex steroid receptor status. Cancer. 1993 ; 72: 2628-2637.
18. Brandt B., Hermann S., Straif K., Tidow N., Buerger H., Chang-Claude J. Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. Cancer Res. 2004 ; 64: 7-12.
19. Bast RC Jr, Pusztai L., Kerns BJ, et al. Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma. 1998 ; 17: 313-321.
20. Goel S., Mani S., Perez-Soler R. Tyrosine kinase inhibitors: a clinical perspective. Curr Oncol Rep. 2002 ; 4: 9-19.
21. Hynes NE, Stern DF The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta. 1994 ; 1198: 165-184.
22. Riben MW, Malfetano JH, Nazeer T., Muraca PJ, Ambros RA, Ross JS Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma. Mod Pathol 1997 ; 10: 823-31.
23. Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol. 1999 ; 18: 138-143.
24. Eccles SA, Modjtahedi H., Box G., Court W., Sandle J., Dean CJ Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy. Invasion Metastasis. 1994-1995 ; 14: 337-348.
25. Berchuck A., Rodriguez G., Kinney RB, et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol. 1991 ; 164: 15-21.
26. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol. 1992 ; 47: 179-185.
27. De Bortoli M, Maggiora P., Capello D., et al. Hormonal control of growth factor receptor expression. Ann N Y Acad Sci. 1996 ; 784: 336-348.
28. Kuraoka K., Matsumura S., Hamai Y., et al. A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer. Int J Cancer. 2003 ; 107: 593-596.
29. Ameyaw MM, Tayeb M., Thornton N., et al. Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet. 2002 ; 47: 172-175.
30. Shintani S., Matsuo K., Crohin CC, et al. Intragenic mutation analysis of the human epidermal growth factor receptor (EGFR) gene in malignant human oral keratinocytes. Cancer Res. 1999 ; 59: 4142-4147.
31. Hsieh YY, Chang CC, Tsai FJ, Lin CC, Tsai CH T homozygote and allele of epidermal growth factor receptor 2073 gene polymorphism are associated with higher susceptibility to endometriosis and leiomyomas. Fertil Steril. 2005 ; 83: 796-799.
32. Huang CM, Tsai CH, Chen CL, Chang CP, Lai CC, Tsai FJ Epidermal growth factor receptor (EGFR) gene Bsr I polymorphism is associated with systemic lupus erythematosus. Lupus. 2004 ; 13: 773-776.
33. Xie D., Shu XO, Deng Z., et al. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst. 2000 ; 92: 412-417.
34. Yokomizo A., Koga H., Kinukawa N., et al. Association of HER-2 polymorphism with Japanese sporadic prostate cancer susceptibility. Prostate. 2005 ; 62: 49-53.
35. Wang L., Habuchi T., Takahashi T., et al. No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer. Int J Cancer. 2002 ; 97: 787-790.
36. Ueda M., Hung YC, Terai Y., et al. HER-2 codon 655 polymorphism in cervical carcinogenesis. Int J Gynecol Cancer. 2006 ; 16: 325-328.
37. An HJ, Kim NK, Oh D., et al. Her2V655 genotype and breast cancer progression in Korean women. Pathol Int. 2005 ; 55: 48-52.
38. McKay JA, Loane JF, Ross VG, et al. c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer. 2002 ; 86: 568-573.
39. Millikan R., Eaton A., Worley K., et al. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat. 2003 ; 79: 355-364.
40. Cox DG, Hankinson SE, Hunter DJ The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet Genomics. 2005 ; 15: 447-450.
41. Fleishman SJ, Schlessinger J., Ben-Tal N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci U S A. 2002 ; 99: 15937-15940.
42. Papewalis J., Nikitin AYu, Rajewsky MF. G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res. 1991 ; 19: 5452.
43. Prat J., Oliva E., Lerma E., Vaquero M., Matias-Guiu X. Uterine papillary serous adenocarcinoma: a 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer. 1994 ; 74: 1778-1783.